At GSK, we are committed to changing the trajectory of high burden diseases in lower income countries with a focus on prevention and treatment of infectious diseases. This is why in 2022, we announced that GSK is investing £1 billion over 10 years to accelerate global health R&D, focusing on new vaccines and medicines to prevent and treat high burden infectious diseases.

Our three-pronged approach, which incorporates global health R&D, access and health system strengthening, is centred on our aim to positively impact the health of 1.3 billion people in lower income countries in this decade. A cornerstone of driving health impact at this scale is partnership. It is through partnership that we can focus on working towards health equity for all.

We believe that by bringing our skills, expertise and passion together with the right partners, we can drive real and sustainable change through our global health focus on developing vaccines and medicines for lower income countries, collaborating for improved access and strengthening health systems.

2023 has seen our R&D teams continue to make great progress in vaccine and medicines candidate development, delivering on our £1bn investment with a special emphasis on TB, malaria, neglected tropical diseases and the field of antimicrobial resistance. Seeing the first shipments of RTS,S leave for countries in sub-Saharan Africa was an incredible moment, after more than 35 years of research and collaboration by GSK and its partners.

In our continued pursuit of sustainable and equitable access, we reached the milestone of delivering 1bn vaccine doses to Gavi, the Vaccine Alliance to help ensure as many children as possible receive vaccines against preventable childhood illnesses. This year also marked a total of 11bn doses of albendazole donated since 2000, to treat and eliminate lymphatic filariasis and soil-transmitted helminths.

We also remained focused on health system strengthening, working with our long-term partners such as Save the Children with the launch of a renewed partnership over the next five years to improve childhood vaccination rates in Ethiopia and Nigeria and Amref Health Africa, with our programme in Kenya and Ethiopia delivering improved prevention, diagnosis and treatment for malaria, TB and HIV. Our investments in local research capacity were also extended, and we continued to lead GSK’s humanitarian response.

Where you are born continues to define your chances of living a healthy life. Until these health inequalities no longer exist, we will stay focused and forge ahead with our partnerships. We can help make a tangible difference in the lives of millions of people, by continuing our investment in research and development, strengthening partnerships, and ensuring access to quality healthcare for everyone.
Looking ahead to 2024, the challenges facing people in lower-income countries are becoming more diverse, and urgent. In reaction, our partnerships are expanding to ensure we are tackling the issues that matter most to the communities we work with, including supporting remote communities within a health system to prepare for the rollout of new malaria vaccines, helping improve health equity for TB, malaria and HIV for women and girls in all their diversity, and reaching zero dose children. Our new strategy for humanitarian response will set us up to respond more effectively to new and protracted crises, as well as aiming to proactively anticipate support that will be needed.

Our partnerships are a source of pride across GSK. Everything we do is shaped by local expertise and stakeholders – they are at the heart of what we do every day. To the many talented, dedicated people working in partnership to get ahead of disease, I’d like to say a heartfelt thank you. I am proud of what has been achieved in 2023 and look forward to our continued partnership and further impact, to help change the trajectory of infectious diseases for generations to come.
# Table of contents

5. The role of GSK’s Impact Partnerships

6. Key programmes

7. Key results: 2022 to 2023

8. 2022 – 2023 programme impact
   - Africa Open Lab
   - GSK x Save the Children, INSPIRING project, Nigeria
     - Integrated sustainable childhood pneumonia and infectious disease reduction in Nigeria
   - GSK x Amref Health Africa
     - Creating an integrated digital learning and reporting tool for front line health workers in Africa: a multi-partner initiative
     - Tackling malaria, TB and HIV in Kenya and Ethiopia

14. New programmes
   - AMR ownership and prevention
     - GSK x Amref Health Africa
       - African leadership for antimicrobial resistance (AMR) action
   - GSK x Save the Children, Zero Dose Programme
     - Increasing child vaccination rates in Ethiopia and Nigeria
   - Malaria prevention
     - GSK x Amref Health Africa
       - Strengthening primary healthcare systems to support malaria elimination in Kenya and Zambia
   - GSK x Last Mile Health
     - Integrating malaria vaccines into community-based primary healthcare in Liberia
   - Integrated TB, HIV, malaria and women & girls
     - GSK x ViiV Healthcare x The Global Fund x Bill and Melinda Gates Foundation, Gender Equality Fund
       - Strengthening engagement and leadership of women and girls in national-level decision making on gender equality and health
     - GSK x mothers2mothers
       - Launching the first integrated tuberculosis (TB) and malaria programme in Uganda and Lesotho (TB only)

17. Humanitarian response

18. GSK people supporting Save the Children’s work

19. Closing statement: What’s next?

20. Charter: Principles we hold ourselves and our partners to

21. References
The role of GSK’s Impact Partnerships

Getting ahead together in global health

To get ahead of disease together, GSK’s ambition is to positively impact the health of at least 2.5 billion people in this decade, including 1.3 billion people in lower-income countries.

Global health is a cornerstone of GSK’s environmental, social and governance (ESG) agenda. We are uniting science, technology, and talent to get ahead of high burden infectious diseases such as malaria and TB in lower-income countries, in the face of increasing global health challenges such as antimicrobial resistance (AMR) and climate change. Our dedicated global health team has a threefold approach to delivering our Global Health ambition:

1. **R&D:** Develop new vaccines and medicines against high burden infectious diseases in lower-income countries.

2. **Access:** Drive equitable access to GSK’s portfolio and pipeline. [Access report]

3. **Impact Partnerships:** Improve health equity for communities that need it most, through catalytic partnerships and funding research in Africa, via the Impact Partnerships team.

Impact Partnerships team

Our Impact Partnerships team aims to improve health equity and contribute towards Sustainable Development Goal 3.3 (SDG 3.3) and universal health coverage (UHC) for TB, malaria and AMR. The team looks to achieve these goals through multi-sector partnerships to achieve improved access, strengthened resilient health systems and research – guided by communities, National Ministries of Health and local experts.

Key areas of work:

1. **Lead health system strengthening partnerships** to improve access to healthcare and research capacity, to drive long-term change, improve health equity and build resilience and self-sustainability.

2. **Lead GSK’s humanitarian response** in lower-income countries and strengthen resilience for infectious disease and climate nexus.

3. **Catalyse health systems and research capacity** using GSK voices to amplify community needs.

At GSK, the Impact Partnerships team also drives employee engagement through sharing stories of people’s experiences, fundraising and volunteering opportunities with partners.

Definitions

The United Nations’ Sustainable Development Goal 3.3 (SDG 3.3) is to end the epidemics of AIDS, TB, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases by 2030.\(^1\)

Universal health coverage (UHC) means that all people have access to the full range of quality health services they need, when and where they need them, without financial hardship.\(^2\)
Key programmes: 2023

Ongoing programmes with impact

Africa Open Lab
Capability support:
- Burkina Faso
- Ethiopia
- Gabon
- Ghana
- Kenya
- Malawi
- Mali
- Nigeria
- Senegal
- South Africa
- Tanzania
- Gambia
- Uganda

GSK x Save the Children - The INSPIRING Project
Nigeria

GSK x Amref x Cognizant - integrated digital learning and reporting tool
- Kenya
- Tanzania
- Ethiopia
- Zambia
- Malawi
- Uganda
- Senegal
- South Africa

GSK x Amref - Tackling malaria, TB and HIV
- Kenya
- Ethiopia

GSK x Amref x Cognizant - integrated digital learning and reporting tool

New partnerships and programmes initiating from 2023/2024

GSK x Save the Children
- Zero Dose Programme
  - Nigeria
  - Ethiopia
- Green Climate Fund:
  - Senegal
  - Malawi

GSK x ViibV Healthcare x The Global Fund x Bill and Melinda Gates Foundation
- Democratic Republic of the Congo
- Eswatini
- Lesotho
- Mozambique
- Nigeria
- Uganda
- Zambia

GSK x Last Mile Health
- Liberia

GSK x mothers2mothers
- Lesotho
- Uganda

GSK x Amref
- Sub-saharan Africa region
- Kenya
- Zambia

An additional 16 countries have been supported through our acute humanitarian response funding
Key results: 2021 - 2023

**Over £24m**
grant funding for health systems strengthening, communities and early-career scientists and humanitarian support (£24,077,292)

32 countries where we have programmes or have supported through emergency funding (16 plus 16 EHR)

2,057,536 people reached through programmes, emergency responses and humanitarian product donation

7,965 community health workers trained

160 academic and scientific researchers – partnered with or trained through Africa Open Lab

£1,791,478 contributed by GSK employees through fundraising, donations and volunteering (gift in kind)
2022 – 2023
programme impact

Africa Open Lab

Africa is home to 16% of the world’s population and accounts for 26% of the global burden of all disease. Yet, the continent represents only 2% of global investment in health R&D, and its scientific output represents 2% of the global share. As such, there are significant gaps in knowledge about the epidemiology of diseases impacting the people of Africa, their clinical presentation and their response to medicines.

To address these knowledge gaps, GSK is supporting African-led research through the Africa Open Lab grant-giving programme. Through this initiative, we are providing funding to support infectious disease researchers in the region, strengthening the capabilities of African scientists at an early stage in their research careers and supporting the development of their networks across the continent.

In 2023, the Africa Open Lab awarded grants to 11 early-career scientists in seven sub-Saharan countries. To date, we have provided approximately £10 million in funding under this programme, supporting 20 projects and resulting in more than 130 scientific publications. The focus of the grants is informed by an independent Scientific Advisory Board of infectious disease experts that helps to identify capability gaps and needs across the African continent.

A further call for proposals was launched in November 2023.

In addition to the grants, Africa Open Lab provides capability-strengthening support based on the gaps identified by the grantees and Scientific Advisory Board. Some examples include:

**Short course in clinical research methods in TB**

In November 2023, a grant was set up to fund a two-week training programme at the School of Public Health-Kwame Nkrumah University of Science and Technology (KNUST) in Ghana to equip African researchers with specialist skills for TB research. The curricula included grant writing, research design, data collection, management and analysis for improved TB management and policy. The 25 participants (10 from Ghana and 15 from other African countries) will also be mentored over the following 12 months.
The Africa Research Excellence Fund's (AREF) Grant Writing Course (to be conducted during 2023 and 2024) includes a focus on increasing participation of female researchers and those from Francophone African countries.

The £90,000 investment will support four grant-writing workshops. Through GSK’s Africa Open Lab support, AREF has increased the number of participants from 40 in 2022 to 58 in 2023, with plans to increase the total number of researchers to benefit from this funding to 82.

The Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine

In November 2023, through collaborative work with The Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, GSK provided scholarships to 35 scholars from a range of backgrounds across early to mid-career positions to attend two interlinked short courses - ‘Introductory Course in Epidemiology and Medical Statistics’ and ‘Essentials in Clinical Trials’. The courses, run in the Gambia, equipped emerging public health leaders with the skills required to accurately design and analyse studies across infectious diseases and non-communicable diseases (NCDs). The courses provided in-depth understanding of the main study designs, the analysis and presentation of epidemiological data, design of clinical trials and the concepts underlying statistical inference and regression analysis, as well as sample size calculations. The course concluded with the creation of alumni groups for networking and follow up on impact.

Dr Alex Kayongo, scientist at the Makerere Lung Institute, and recipient of Africa Open Lab funding in Uganda.

“My journey really, really sparked off in 2018 when I got the [Africa] Open Lab NCD project. GSK gave me a chance to come up with this highly bold idea [and] to try it out. Throughout the whole period, there was that intensive back-to-back interaction with GSK scientists, and, along that time, my skills really improved. I was elevated from thinking at a local perspective to really an international perspective. So, my mind really changed. And when my mind changed, everything really changed. After GSK opened the project, we really got fantastic results. That helped give us background for further funding that we’re able to get.”

As GSK looks to change the trajectory of infectious diseases, our Africa Open Lab funding will continue to focus on building local, African-led research capabilities, targeting early-career researchers with a focus on malaria, TB, and AMR.

“It still feels too good to be true that I had the wonderful opportunity granted by the GSK scholarship to participate in ICEMS. I remember fondly the team spirit that was prevalent throughout the training, the hospitality received from the MRCG team and the way the professors delivered the materials engagingly. I remain indebted to them for equipping me with this new knowledge and expertise and I am equally indebted to you and wish to express my sincere gratitude to GSK.

I encourage GSK to continue providing Africa with support as it needs more health researchers coming from different disciplines. As a completing PhD candidate in Health Policy and Systems Research, I surely will use the training to expand my horizon and to contribute wisely to the field of Health Policy and Systems Research.”

Participant on the MRC Gambia @LSHTM courses
Since 2013, GSK has partnered with Save the Children, combining skills, expertise, and resources to find new ways to reduce preventable child deaths. The partnership has included six major country programmes – in Nigeria, Ethiopia, Kenya, Yemen, Democratic Republic of the Congo; and a founding partner for Save the Children’s Emergency Health Unit – to create long-term innovative impact and strengthen healthcare systems. The Emergency Health Unit provides urgent response to humanitarian crises, and from this a model of preparedness and rapid response was created.

The partnership has a strong and well-established governance structure in place. It is led by a Joint Steering Committee with equal representation from both organisations, and a Joint Working Group that manages day-to-day operations and technical committee. The governance structure ensures strategic alignment, accountability, risk management, stakeholder engagement and compliance, with Save the Children responsible for decision-making.

Approximately five million children under the age of five die each year globally, with infectious diseases, including pneumonia, diarrhoea, and malaria, along with pre-term birth complications, remaining the leading causes of death.\(^5\)

3.5 million+ children reached across 51 countries

240,000 children under five immunised against key preventable diseases

807,200+ cases of malaria, pneumonia or diarrhoea in children treated

39,470 health workers trained, and 21,480 community health workers supported

400,000 children under five received help and support during and after emergencies

Mothers wait for the mobile vaccination team to arrive in a remote community in Jigawa State, Nigeria

Healthworker Nura Ibrahim administers a vaccine

Saratou, who has recently recovered from pneumonia, outside their home in Jigawa State, Nigeria
Over the past decade, we also collated data and published 12 reports to influence healthcare policies and further increase access to healthcare. Through employee engagement, we raised £5.6 million, thanks to fundraising efforts in more than 70 countries.

An example of the programme results includes the INSPIRING project (Integrated Sustainable Childhood Pneumonia and Infectious Disease Reduction in Nigeria):

The INSPIRING project aimed to provide directly applicable evidence of what works to reduce the burden of childhood pneumonia, with the research programme organised in two Nigerian states, Jigawa and Lagos, from April 2018 to May 2023. The project started with an inception phase to understand the challenges related to pneumonia in the two states, which then fed into the design of the programme strategy.

The programme upskilled health workers with specialist paediatric training to improve care of children with pneumonia.

<table>
<thead>
<tr>
<th>101</th>
<th>taught integrated management of childhood illness</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
<td>upskilled on paediatric nutrition</td>
</tr>
<tr>
<td>10</td>
<td>trained as trainers in oxygen therapy</td>
</tr>
<tr>
<td>60</td>
<td>trained on immunisation</td>
</tr>
<tr>
<td>35</td>
<td>trained in pulse oximetry and oxygen therapy</td>
</tr>
</tbody>
</table>

The project resulted in accelerated reduction of pneumonia-related child mortality, as well as deaths from other preventable infectious diseases through health system strengthening, including community education programmes like a radio programme. Our programme in Jigawa demonstrated a 9% reduction in child mortality (from 185/1000 livebirths to 171/1000), through interventions focused on improving community health-seeking behaviours, with an increase in caregivers’ awareness of the signs and symptoms of pneumonia.

“Before the radio programme, I did not believe in taking my children to the clinic. I believed the traditional and the spiritual method is the best way and the one our forefathers used. After listening to the radio programme and the community health volunteer (CHV) during her visits, I was able to learn the importance of taking my children to the clinic for proper treatment when they are sick and also take them for immunisation.”

Sabon Gari, community member, Tsirma ward, Kiyawa LGA

The five-year programme improved the quality of child health services in both states and increased access and use of these services within a supportive community environment in Jigawa State. The project also led to the publication of 11 research papers and articles. These data will be used to support development of policies and guidelines that foster universal access to maternal, newborn and child health services, including necessary governance structures and policy frameworks. A final research report, including impact evaluation, process evaluation and economic evaluation was published in 2023.
Africa is disproportionately impacted by the global disease burden, particularly from infectious diseases, including malaria, TB and HIV.\textsuperscript{6}

For example, the continent, which is home to 14\% of the world’s population, accounted for an estimated 94\% of all malaria cases in 2019.\textsuperscript{6,7} To address this disease burden, healthcare systems need to be well-equipped to support communities and improve both prevention and treatment.

GSK has partnered with Amref Health Africa for over 35 years to make lasting health change in Africa; working closely with the full healthcare ecosystem, from communities to governments to international organisations. The programmes focus on building capacity through health system strengthening, including health worker training, improving supply chains and “last mile” access, health financing and disease surveillance.

Amref co-creates its programmes with recipient country Ministries of Health, communities and local community-based organisations. During the programme period, there are quarterly meetings between all partners. GSK convenes Project Steering Groups that meet quarterly for programmes involving colleagues from GSK Global Health and Amref (in-country and UK teams) to provide programme oversight and governance across the programme. Amref also produces progress reports every six months.
Two projects designed to create long-lasting impact among communities in Africa include:

Creating an integrated digital learning and reporting tool for frontline health workers in Africa: A multi-partner initiative (April to November 2022)

GSK and Amref partnered with Cognizant to develop an integrated mobile training and reporting platform for community health workers. The project was funded by GSK and Cognizant and included clear key performance indicators and a communications plan to share this approach to other private sector and non-governmental organisation partners. The training platform and dashboards were successfully deployed across three sub-Saharan countries (Kenya, Senegal and Zambia) and addressed a significant unmet need, enhancing the capability and impact health workers were able to deliver to communities. The dashboards now support health teams to use data effectively to make decisions around health worker training in line with the needs of the community; 100% of users surveyed agree or strongly agree that the information displayed is useful for their work.

Tackling malaria, TB and HIV in Kenya and Ethiopia (2021 to 2022)

To promote earlier prevention, diagnosis, referral and treatment for malaria, TB and HIV, £2.7 million (£2.4 million GSK/£300,000 ViiV-Positive Action) was granted to fund a two-year community-based health system strengthening programme in Kenya and Ethiopia. It was also aligned to national disease strategies to address gaps in funding. The programme demonstrated clear progress and significant impact, with over 6,000 health workers trained and 370 health facilities supported. Community education projects resulted in 70% of community members now seeking prompt care. Additionally, the programme resulted in an increased county budget in Kenya and mobile TB screening in Ethiopia.

The partnership continues to work to establish resilient healthcare systems across Africa to withstand emerging challenges affecting the region, including malnutrition, AMR and inadequate water, sanitation and hygiene (WASH), as well as climate shocks.

“I trained on treating and diagnosing malaria. My main job is to sensitisate the community about diseases like malaria, TB, hypertension, HIV and so many other diseases. In the community, we have some people who don’t want to go to the hospital to queue up, so when they are sick, they remain in the house and they don’t seek medication. I am here and I always visit these households twice a month. I feel good because I’m helping the community. I’m very happy to be a volunteer.”

Gaudenciah Wauyama, Amref Community Health Promoter, Busia, Kenya
New programmes

AMR ownership and prevention

African leadership for AMR action (GSK x Amref)

GSK and Amref developed an AMR programme in 2023. In this programme, Amref will leverage its leadership position in Africa to help convene key stakeholders such as the Africa Centres for Disease Control and Prevention (CDC), World Health Organization Regional Office for Africa (WHO-AFRO), Ministries of Health and Civil Society to support implementation of regional and national AMR plans. Projects will include situational analysis to understand the status of AMR action in the region and development of an advocacy messaging framework. The programme will create a regional AMR Action Group and ensure these plans are sustainably embedded and financed locally to establish longevity beyond the project period.

The findings will be published externally and used to strengthen AMR programming in the region, implemented through locally led and owned multisector collaborations. They will also be integrated into an Amref-GSK proposed malaria programme in Kenya and Zambia, since increasing resistance to malaria treatments threatens the prospect of malaria elimination.

Zero Dose Programme (GSK x Save the Children)

In 2023, GSK renewed its award-winning 10-year partnership with Save the Children for another five years, with a focus on “zero dose” children – those who have never received any routine vaccinations. With a £15 million investment from GSK, the partnership aims to increase child vaccination rates in Ethiopia and Nigeria, finding local, holistic solutions to this significant issue. In addition, we intend to understand, address and share the research and potential solutions for this critical question to prevent diseases and AMR from occurring. Led by communities and working with local health centres, governments and other partners, the two programmes will support improved access to routine vaccination services and work with “missed communities” to educate them on the importance of vaccinations and communicate findings across the region.

Additional climate programme

We recognise that the climate crisis is one of the biggest emerging threats to children’s survival, so we are ensuring all programmes in climate-sensitive countries are appropriately adapted. In 2023, we invested in Save the Children’s Anticipatory Action, in the Horn of Africa, seed funding the full design of two ground-breaking climate health adaptation projects with partner governments in Malawi and Senegal.
New programmes

Malaria prevention

Strengthening primary healthcare systems to support malaria elimination in Kenya and Zambia (GSK x Amref)

GSK and Amref have created a three-year programme, Strengthening Primary Healthcare Systems for Malaria Elimination (PHC for ME) in Kenya and Zambia to improve community health systems, build a fit-for-purpose health workforce and strengthen civil society organisations. The programme, which is launching in 2024 with a £4.5 million GSK investment, aims to deliver strong measurable impact that is evidence-based and sustainable. The outcomes of each programme phase will be measured and publicly reported.

Integrating malaria vaccines into community-based primary healthcare in Liberia (GSK x Last Mile Health)

In 2023, GSK expanded its partnership with Last Mile Health to implement essential malaria services in Liberia. This partnership aims to support remote communities with the integration of malaria vaccination into current routine vaccination protocols and into the suite of standard malaria prevention interventions, such as insecticide-treated bed nets, good sanitation and hygiene and medicines. The programme will engage community health workers on malaria vaccine delivery, provide community-level data on malaria vaccines and routine immunisations available, as well as driving administration of malaria vaccines. This work complements the wider malaria vaccine programme being implemented by the Ministry of Health and Gavi.
New programmes

Integrated TB, HIV, malaria and women & girls

Launching the first integrated TB and malaria programme in Uganda and Lesotho (TB only) (GSK x mothers2mothers)

GSK partnered with mothers2mothers (m2m) in 2023 to develop an integrated TB and malaria programme in Uganda and Lesotho (TB only). m2m is incorporating TB and malaria into community-based integrated primary healthcare services through the m2m Peer Mentor model.

Over the next year, our partnership with m2m will deliver direct health services along with health education and health system strengthening to overcome barriers around the knowledge of, access to and treatment for these preventable and life-threatening diseases.

Across Lesotho and Uganda, m2m aims to reach children (0-14 years), adolescent girls and young adults, pregnant and breastfeeding mothers, and other household community members. The partnership will periodically measure the success of the programme against these objectives and amplify voices from the communities in Lesotho and Uganda to strengthen our understanding and insights into the lived experiences of patients and caregivers.

Gender Equality Fund (GSK x ViiV Healthcare x Bill and Melinda Gates Foundation x The Global Fund)

GSK and ViiV Healthcare partnered with The Global Fund to Fight AIDS, TB and Malaria in 2023, committing £6 million over three years for a Gender Equality Fund (GEF). Through implementing partners, the GEF aims to strengthen the engagement and leadership of women and girls in national-level decision making on gender equality and health, with a focus on HIV, TB and malaria. The partnership will also increase the capacity and advocacy for community-led and -based organisations to deliver gender-transformative and gender-affirmative approaches to health.

In October 2023, the GEF launched a Request for Information to gauge interest from women-led, community-based organisations and consortia in Democratic Republic of the Congo, Eswatini, Lesotho, Mozambique, Nigeria, Uganda and Zambia, followed by a full Request for Proposals. Successful proposals will receive funding for the 2024 to 2026 period.
Humanitarian response

Humanitarian crises – including disease outbreaks, natural disasters, and human conflict – continue to impact millions of people across the world, leaving populations vulnerable to their consequences and healthcare systems ill-equipped to respond to shocks. When this occurs, a widespread humanitarian response is critical to addressing the factors impacting human lives, aiding recovery of communities and rebuilding the infrastructure needed to sustain them.

Our overall goal is to save lives and support access to healthcare for communities in humanitarian contexts through timely disaster response and strengthening resilience in countries disproportionately impacted by infectious disease and climate-exacerbated shocks. We do this by:

- Responding to rapid onset disasters - cash grants and product donations
- Improving access to healthcare in protracted crises
- Strengthening resilience for infectious diseases and climate shocks

In 2023, GSK supported key humanitarian partners, including British Red Cross, Save the Children and United Kingdom for United Nations High Commissioner for Refugees (UNHCR), and others, to deliver humanitarian and disaster relief assistance in Gaza, Israel, Libya, Morocco, Syria, Türkiye and Ukraine.

Product donations for humanitarian response

Our product donation programme has delivered high-quality medicines to disaster-affected communities for over 20 years. Approximately 150,000 units of broad-spectrum antibiotics (broadly equivalent to 150,000 people reached) are distributed by GSK in up to 20 countries annually. By collaborating with charity partners, Direct Relief and International Health Partners, we ensure a continuous and reliable supply of long-dated, high-quality products which meet the needs of communities. GSK and its partners are members of the Partnership for Quality Medical Donations (PQMD), which enables liaison with the members, especially during disasters, to coordinate responses. This is in addition to GSK’s albendazole donation programme which to date has supplied more than 11 billion doses of the medicine to help eliminate lymphatic filariasis and treat soil-transmitted helminths.

[access report here]

Emergency Health Unit

As part of our Save the Children partnership, the Emergency Health Unit was co-founded in 2015 to create an expert team strategically positioned in disaster hotspots that can deliver emergency healthcare within 72 hours of disaster onset. From 2022 to 2023, GSK contributed £1 million to strengthen Save the Children’s “Anticipatory Action” (AA) capability to respond to climate-related emergencies, reducing and mitigating the health impact on vulnerable and at-risk communities. The funding enabled the development of AA tools, systems and protocols which establish predictable and forecast-based actions with defined triggers and indicators. These have been disseminated widely across Save the Children’s humanitarian teams, the Emergency Health Unit and local partners so that early action can be initiated at the first signs of risk.

The Emergency Health Unit and GSK won the Business Charity Award for “Best Emergency Response Project” for 2022, recognising the rapid deployment of teams in humanitarian crises to offer life-saving treatment for children.
GSK people supporting Save the Children’s work

Fundraising

The power of our Save the Children partnership is driven by the commitment, generosity and determination of GSK employees who, since 2013, have raised over £6 million.

Through Orange United, our employee engagement programme, GSK staff are changing the trajectory for millions of young people by fundraising for Save the Children. Currently, there are 214 Orange United Ambassadors in 34 countries. All funds raised by GSK employees are matched by GSK and contributed to Save the Children’s work globally. Employees get involved in a myriad of innovative ways, including Trek for Kids, a six-day international trek in which 120 employees have visited Save the Children programmes, raising more than £800,000 in the process.

Future partnerships

Excitingly, we are expanding Orange United through a new partnership with Amref Health Africa, where the GSK team hopes to improve wellbeing across the continent.

Volunteering and secondments

As well as raising money, staff are supporting Save the Children to become more efficient and effective. Secondments of GSK supply and procurement professionals are saving them at least $500,000 each year. Through three-, six- and twelve-month placements, more than 100 employees have supported Save the Children virtually and in local communities across the world by volunteering in skills- and community-based roles during working hours.

In June 2023, GSK launched its new skills-based volunteer programme. All GSK and ViiV Healthcare regular employees can volunteer for one or two days each year by taking part in team-based, hands-on Together Days or through skills-based volunteering. In the first six months of the programme, 167 volunteers supported Save the Children’s work.
Closing statement: What’s next?

GSK’s Impact Partnerships are designed to support global efforts to achieve health equity, with a particular focus on TB, malaria and AMR. Through multi-sector partnerships, we are improving access to medicines, making more resilient health systems and strengthening in-country research, all the while working hand in hand with communities and local experts.

We are proud of the impact of our partnerships. But, with our partners and partnerships, we will not stop. In 2024, we are aiming to reach one million people — and 10 million by 2026. Crucially, this impact will be sustainable, build resilience for health systems and support efforts to achieve universal health coverage, as everyone should have access to quality healthcare, wherever they are.
Charter: Principles we hold ourselves and our partners to

We continue to work towards advancing health equity for all. We use our decision-making frameworks and compliant culture to work with partners in line with our principles, including:

1. We are guided by local communities, experts and stakeholders and support local ownership, leveraging GSK talent.

2. We take an integrated holistic approach of health system strengthening to achieve:
   - health sustainability and prevention and/or
   - resilience to climate shocks and/or
   - to pave the way for innovation to those who need it most.

3. Catalytic Partnerships to drive sustainability, scalability and health equity impact.

The Global Health Impact Partnership’s team operates within GSK’s Governance Framework, to ensure oversight and that we deliver our programmes and activities in line with our Global Health Strategy. We can only deliver on our bold ambitions for patients and communities if we maintain a well-embedded risk management and internal control framework, that is overseen by the leadership team.

This is a key part of GSK’s culture of being ambitious for patients, accountable for impact and doing the right thing, and the framework provides a guiding principle and one way of working within Global Health.

Within Global Health, this is our decision framework:

For every impact partnership programme we run, we have specific programme governance in place to ensure we remain accountable, and decision-making is clear. This includes a named GSK programme lead and joint steering committee.

Dedicated committees

- Monthly LT meeting
- GH Monthly Investment Board
- Annual GH Investment Board
- Non R&D GH Grants and Donations
- GH & Department Risk Management Board
- Joint Programme Steering Committees
- AOL Scientific Advisory Board
References

3 UNAIDS. Africa-Europe Week: Investing in health is investing in economic recovery: Financing for HIV, stronger public health systems, and pandemic preparedness and response — UNAIDS Executive Director remarks. 2022.
4 World Economic Forum. There are not enough scientists in Africa. How can we turn this around? 2017.